Shares of Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) were up 5.1% on Wednesday . The stock traded as high as $18.92 and last traded at $18.82. Approximately 117,599 shares traded hands during trading, a decline of 74% from the average daily volume of 456,457 shares. The stock had previously closed at $17.91.
Analyst Ratings Changes
Several brokerages recently weighed in on CYRX. Needham & Company LLC reduced their target price on shares of Cryoport from $19.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, March 13th. UBS Group boosted their target price on shares of Cryoport from $14.50 to $17.00 and gave the stock a "neutral" rating in a research report on Friday, March 15th. Finally, Stephens reaffirmed an "equal weight" rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $18.29.
View Our Latest Research Report on CYRX
Cryoport Price Performance
The stock has a 50 day moving average price of $16.28 and a two-hundred day moving average price of $14.51. The company has a debt-to-equity ratio of 0.82, a quick ratio of 11.16 and a current ratio of 11.73. The company has a market capitalization of $898.29 million, a PE ratio of -8.34 and a beta of 1.60.
Insider Activity at Cryoport
In other news, CEO Jerrell Shelton sold 57,039 shares of the business's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $15.30, for a total transaction of $872,696.70. Following the completion of the sale, the chief executive officer now owns 634,352 shares in the company, valued at $9,705,585.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Ramkumar Mandalam sold 3,217 shares of the company's stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the sale, the director now owns 43,187 shares in the company, valued at $633,985.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 57,039 shares of the company's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $15.30, for a total value of $872,696.70. Following the completion of the sale, the chief executive officer now owns 634,352 shares in the company, valued at approximately $9,705,585.60. The disclosure for this sale can be found here. Insiders have sold a total of 73,940 shares of company stock valued at $1,147,538 in the last 90 days. 10.50% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Cryoport
A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Cryoport by 19.4% during the 1st quarter. JPMorgan Chase & Co. now owns 33,229 shares of the company's stock worth $1,160,000 after acquiring an additional 5,398 shares during the last quarter. US Bancorp DE lifted its holdings in Cryoport by 16.6% during the 1st quarter. US Bancorp DE now owns 24,191 shares of the company's stock worth $844,000 after buying an additional 3,448 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Cryoport by 50.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,053 shares of the company's stock worth $280,000 after buying an additional 2,696 shares during the period. AlphaCrest Capital Management LLC lifted its holdings in Cryoport by 64.3% during the 1st quarter. AlphaCrest Capital Management LLC now owns 11,007 shares of the company's stock worth $384,000 after buying an additional 4,307 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in Cryoport by 59.9% during the 1st quarter. MetLife Investment Management LLC now owns 21,874 shares of the company's stock worth $764,000 after buying an additional 8,194 shares during the period. Institutional investors own 92.90% of the company's stock.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
